Fijn dat je er bent!
Wij maken op onze website gebruik van cookies. Geef per categorie jouw keuze voor het gebruik van cookies aan. Lees meer over de cookies in onze cookieverklaring. Wil je de beste website ervaring? Vink dan alle vinkjes aan.
- Sessie cookies
- Inlog cookies
- Google Analytics
- Google Maps
- YouTube
- Social Media
- Facebook


Aantal medewerkers

Over deze organisatie

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA and now has offices in a number of European countries including the Netherlands.
Lees meer

‘’I have never worked for a company where individual and team contributions are so frequently and openly shared, acknowledged and celebrated. This, plus the welcoming and collaborative attitude of all Alnylam-ites and the company’s can-do mentality has made this my favorite place to work!’’
Jessica Diez Canseco Quintana - Turfboer
Lees meer

Great Place to Work over

Alnylam meets the criteria of Great Place to Work. Based on the required minimum score on the Great Place to Work employee survey Alnylam is certified. 

The employees score Alnylam the highest on Camaraderie and Pride. The statement ‘When I look at what we accomplish, I feel a sense of pride’ has a score of 100%. 

Lees meer

At Alnylam we take a bold view of translating scientific research into a pipeline of new drugs. The positive and highly engaged culture of our team of people with different skills, experiences and backgrounds is key to bringing these medicines successfully to patients
Marco Fossatelli
Lees meer
020 260 06 94
©2022 Great Place to Work® Institute Inc. All Rights Reserved.
made with by CIC